In response to the recent outbreak of the new coronavirus COVID-19, MGI are initiating scientific collaborations in Europe, which will support scientific research and technology development based on the DNBSEQ platform, such as development of novel coronavirus detection methods, virus mutation monitoring, tracing, pathogenesis, prediction, and treatment of infection.

In face of the war against novel coronavirus, MGI’s DNBSEQ series of high-throughput sequencers are used in pneumonia prevention phenomena and control. On December 30, 2019, in the earliest batch of 13 new types of coronavirus genome sequence data submitted to the global shared influenza virus database GISAID, five cases of data were obtained from MGI's DNBSEQ-G400. The study and analysis of the evolutionary sources and pathogenesis of the new coronavirus in Wuhan provided first-hand information.

MGI will provide scientific research support, including sequencing with the world's highest daily throughput sequencer DNBSEQ-T series, powered by DNBSEQ^TM  core technology, which features high accuracy, low error rate and no index hopping. Innovative genome technologies will help to untangle the complex picture of coronavirus spread and develop novel technologies in infectious disease control. 

How to participate:

a) The project should focus on COVID-19 scientific research/ virus detection, with plans to ultimately publish the research in a scientific journal. 

b) After the paper is published, the data shall be archived in the CNSA database. Submit your brief proposal to mgi.lv@genomics.cn before April 30, 2020. 

c) MGI will review the proposals and select projects which involve highly relevant research subjects of public significance and technology development related to COVID-19.

d) Sample type: DNBSEQ sequencing libraries

e) Sequencing will be done on the DNBSEQ platform with no charge for selected projects.